BANNOCKBURN, Ill., Feb. 26, 2025 (GLOBE NEWSWIRE) — Option Care Health, Inc. (the “Company” or “Option Care Health”) (Nasdaq: OPCH), the nation’s largest independent provider of home and alternate site infusion services, announced today financial results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter 2024 Financial HighlightsNet revenue of $1,346.4 million, up 19.7% compared to $1,124.4 million in the fourth quarter of 2023 Gross profit of $268.4 million, or 19.9% of net revenue, up 8.6% compared to $247.1 million, or 22.0% of net revenue, in the fourth quarter of 2023 Net income of $60.1 million, compared to net income of $57.2 million, in the fourth quarter of 2023 and diluted earnings per share of $0.35, up 9.4% compared to diluted earnings per share of $0.32 in the fourth quarter of 2023 Adjusted...

TORONTO, Feb. 26, 2025 (GLOBE NEWSWIRE) — Sprott Inc. (NYSE/TSX: SII) (“Sprott” or the “Company”) today announced its financial results for the year ended December 31, 2024. Management commentary “Sprott’s Assets Under Management (“AUM”) ended the year at $31.5 billion, down 6% from $33.4 billion as at September 30, 2024, but up 10% from $28.7 billion as at December 31, 2023. 2024 was our seventh consecutive year of double-digit AUM growth and, subsequent to year-end, as at February 21, 2025, AUM had further increased to $33.5 billion, up $2 billion, or 6% from December 31, 2024,” said Whitney George, Chief Executive Officer of Sprott. “During the year we benefited from strong precious metals prices as well as $698 million in net sales, primarily in our physical trusts and uranium and critical materials ETFs.” “The...

Worldwide revenue of $391.1 million and $1.53 billion for the fourth quarter and full year 2024 Free cash flow was $141.4 million and $493.1 million for the fourth quarter and full year 2024 GAAP fully diluted loss per share of $(0.17) and earnings per share of $4.36 for the fourth quarter and full year 2024 Adjusted fully diluted earnings per share of $1.59 and $6.76 for the fourth quarter and full year 2024 PYLARIFY exceeds $1 billion in net sales and becomes first ever blockbuster radiodiagnostic Company announces a series of strategic asset and in-licensing deals that is expected to diversify its portfolio with early- to late-stage assets that position the company for continued growth in high potential markets Company provides full year 2025 revenue and adjusted diluted earnings per share guidanceBEDFORD, Mass., Feb. 26, 2025 ...

Fourth Quarter Net Sales Increased 20% with Full Year Increasing 5% to $516 million benefiting from Vita Coco Coconut Water growth of 10%  Full Year Net Income Increased $9 million to $56 million and Non-GAAP Adjusted EBITDA1 Increased $16 million to $84 million For Fiscal Year 2025, Expect Net Sales between $555 and $570 million and Adjusted EBITDA2 between $86 and $92 million NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) — The Vita Coco Company, Inc. (NASDAQ:COCO) (“Vita Coco” or “the Company”), a leading high-growth platform of better-for-you beverage brands, today announced financial results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter and Full Year 2024 Highlights Compared to Prior YearNet sales increased 20% in the fourth quarter to $127 million resulting in full year net sales of $516 million. Vita...

— Fourth quarter 2024 net revenue from global sales of IMCIVREE® (setmelanotide) of $41.8 million — — On track to report topline data from global Phase 3 trial evaluating setmelanotide in acquired hypothalamic obesity in the second quarter of 2025 —  — Completed enrollment in the Phase 2 trial of oral MC4R agonist bivamelagon in acquired hypothalamic obesity — — FDA approved expanded label for IMCIVREE to include children as young as 2 years old — — Raised approximately $75 million in gross proceeds under ATM equity offering program; Cash runway extended into 2027 — — Management to host conference call today at 8:00 a.m. ET — BOSTON, Feb. 26, 2025 (GLOBE NEWSWIRE) — Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company...

2024 Net Income of $19.2 million Annual EBITDA1 of $68.8 million and Free Cash Flow to Equity1 of $27.8 million 14th Quarterly Dividend of Cdn$0.03 Declared $21.2 million Returned to Shareholders in 2024 VANCOUVER, British Columbia, Feb. 26, 2025 (GLOBE NEWSWIRE) — Amerigo Resources Ltd. (TSX: ARG; OTCQX: ARREF) (“Amerigo” or the “Company”) is pleased to announce financial results for the year and three months (“Q4-2024”) ended December 31, 2024. Dollar amounts in this news release are in U.S. dollars unless indicated otherwise. Amerigo’s annual financial results included annual net income of $19.2 million, earnings per share (“EPS”) of $0.12, EBITDA1 of $68.8 million and free cash flow to equity1 (“FCFE1”) of $27.8 million. In 2024, Amerigo returned $21.2 million to shareholders, including Cdn$.16 per share of quarterly and performance...

Achieved record positive Adjusted EBITDA* of $20 million for FY2024 (net loss of $8.3 million), exceeding latest guidance of $17-19 millionAchieved record quarterly revenue of $25 million and annual revenue of $85.9 millionNew credit facilities’ favorable interest rates and amortization schedules free up approximately $19 million in cash in 2025In-licensed two new Ionis assets in Canada to drive long-term growthMONTREAL, Feb. 26, 2025 (GLOBE NEWSWIRE) — Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a specialty biopharmaceutical company focused on the commercialization of innovative therapies that have the potential to redefine standards of care, today reported business highlights and financial results for the fourth quarter and full year of fiscal year 2024, ended November...

Consolidated revenues were $736 million, up 8.6% on a consolidated and an organic constant currency (OCC) basis for the fourth quarter of 2024. For the full year 2024, consolidated revenues were $2,882 million, up 7.5% and up 7.1% on an OCC basis. Income from continuing operations was $204 million, up 11.6% for the fourth quarter of 2024. Adjusted EBITDA, a non-GAAP measure, was $398 million, up 9.9%, and up 13.5% on an OCC basis. For the full year 2024, income from continuing operations was $951 million, up 23.7%, while adjusted EBITDA was $1,576 million, up 9.9%, on a consolidated and OCC basis. Diluted GAAP earnings per share from continuing operations (diluted EPS attributable to Verisk) were $1.44 for the fourth quarter of 2024, up 15.2%. Diluted adjusted earnings per share from continuing operations (diluted adjusted EPS), a non-GAAP...

Consolidated earnings per diluted share of $2.29 for the full year of 2024 Initiated consolidated guidance of $2.52 to $2.72 per share for 2025SPOKANE, Wash., Feb. 26, 2025 (GLOBE NEWSWIRE) — Avista Corp. (NYSE: AVA) today announced financial results for 2024. Net income and earnings per diluted share for the fourth quarter and the year ended Dec. 31, 2024 compared to the same periods in 2023 are presented in the table below (dollars in millions, except per-share data):  Fourth Quarter     Year-to-Date    2024     2023     2024     2023  Net Income (Loss) by:                      Reportable Segments                      Avista Utilities $ 68     $ 83     $ 179     $ 167  AEL&P   3       3       8       9  Other non-reportable segment loss   (4 )     (2 )     (7 )     (5 )Total net income $ 67     $ 84     $ 180     $ 171  Earnings...

NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) — Taboola (Nasdaq: TBLA), a global leader in delivering performance at scale for advertisers, today announced its results for the fourth quarter and full year ended December 31, 2024. “2024 proved to be a transformative year for Taboola,” said Adam Singolda, CEO of Taboola. “Our team remained focused and dedicated, delivering the strong results we set out to achieve two years ago. This past year, we learned that advertisers are looking for more—and we’re ready to deliver. Today, we’re excited to announce our expansion into all performance advertising with the launch of Realize, our new independent performance platform that goes beyond search and social. Our investments in 2025 will enable Realize to increasingly empower our advertisers to achieve their desired outcomes at scale, using our...